Hepatocellular carcinoma (HCC) is one of the most common solid malignancies worldwide.
A large proportion of patients with HCC are diagnosed at advanced stages and are only …

Background Immunotherapy has determined unprecedented long-term responses in several
hematological and solid tumors. In the MOUSEION-03 study, we conducted a meta-analysis …

Background & Aims The tumour microenvironment (TME) is a crucial mediator of cancer
progression and therapeutic outcome. The TME subtype correlates with patient response to …

Multidimensional analyses have demonstrated the presence of a unique tumor
microenvironment (TME) in liver cancer. Tumor‐associated macrophages (TAMs) are …

Hepatocellular carcinoma (HCC) has high relapse and low 5-year survival rates. Single-cell
profiling in relapsed HCC may aid in the design of effective anticancer therapies, including …

Immune-based therapies such as immune checkpoint inhibitors have revolutionized the
systemic treatment of various cancer types. The therapeutic application of monoclonal …

A new mode of cell death, disulfidptosis, has been discovered. Clinical prognostic
significance of disulfidptosis related pattern in hepatocellular carcinoma (HCC). In this study …

Cancer immunotherapy (CIT) with antibodies targeting the programmed cell death 1 protein
(PD-1)/programmed cell death 1 ligand 1 (PD-L1) axis have changed the standard of care in …

Hepatocellular carcinoma (HCC), one of the most fatal malignancies in the world, is usually
diagnosed in advanced stages due to late symptom manifestation with very limited …

Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer with poor
prognosis. Surgery, chemotherapy, and radiofrequency ablation are three conventional …